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BLAST analysis of expressed sequence tags (ESTs) us­
ing the coding sequence of the human UDP-galactose: /3- 
iV-acetylgluc os amine /31,4-galactosyltransferase, desig­
nated /34Gal-Tl, revealed a large number of ESTs with 
identical as well as similar sequences. ESTs with se­
quences similar to that of /34Gal-Tl could be grouped 
into at least two non-identical sequence sets. Analysis of 
the predicted amino acid sequence of the novel ESTs 
with /34Gal-Tl revealed conservation of short sequence 
motifs as well as cysteine residues previously shown to 
be important for the function of /34Gal-Tl. The likeli­
hood that the identified ESTs represented novel galac- 
tosyltransferase genes was tested by cloning and se­
quencing of the full coding region of two distinct genes, 
followed by expression. Expression of soluble secreted 
constructs in the baculovirus system showed that these 
genes represented genuine UDP-galactoseijS-iV-acetyl- 
gluc os amine /31,4- galactosyltransferases, thus desig­
nated /34Gal-T2 and 04Gal-T3. Genomic cloning of the 
genes revealed that they have identical genomic organi­
zations compared with /34Gal-Tl. The two novel genes 
were located on lp32-33 and lq23. The results demon­
strate the existence of a family of homologous galacto- 
syltransferases with related functions. The existence of 
multiple (34-galactosyltransferases with the same or 
overlapping functions may be relevant for interpreta­
tion of biological functions previously assigned to 
04Gal-Tl.
During the last decade, more than 40 mammalian glycosyl- 
transferases have been cloned and characterized (1, 2). The 
initial strategy for cloning glycosyltransferases was cumber­
some purification of labile enzyme proteins followed by screen­
ing of cDNA libraries with antibodies or DNA probes based on 
amino acid sequence information (3-11). The introduction of
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transfection cloning by Lowe and co-workers (12) resulted in a 
marked increase in the cloning of novel glycosyltransferase 
genes (13-17). A third successful approach has taken advan­
tage of conserved sequences in glycosyltransferases that share 
donor and/or acceptor substrates. Thus, searches for novel 
members of homologous glycosyltransferase gene families uti­
lizing conserved sequence motifs for RT-PCR1 cloning with 
degenerate primers have resulted in the identification and 
cloning of a number of novel genes (18, 19).
One part of the human genome project is the establishment 
of a data base of expressed sequence tags (ESTs), which cur­
rently has over 700,000 unique sequences. ESTs represent 
short 5'- and 3'-sequences (200-500 bp) of cDNA clones from a 
large variety of human and animal organs (20). The EST data 
base is now estimated to contain sequence information from 
more than half the human genes; it therefore provides a unique 
source for identifying novel members of homologous gene fam­
ilies (21). The EST data base has recently been successfully 
utilized in searches for novel glycosyltransferase genes of the 
UDP-GalNAc¡polypeptide Af~acetylgalactosaminyltransferase 
family, where several novel members of this homologous gene 
family have been isolated by identification of ESTs with se­
quence similarities (22, 23).
A number of homologous families of glycosyltransferase 
genes exist. The largest family identified so far is the sialyl- 
transferase family, for which at least 11 distinct members have 
been identified (24). Sequence motifs shared between sialyl- 
transferases are part of the catalytic domain, suggesting that 
conservation of these sequences is related to functional require­
ments (25). Additional homologous glycosyltransferase gene 
families include the a2- and a3/4-fucosyltransferase families
(26), the tt3-GalNAc-transferase family (27), the |36-GlcNAc- 
transferase family (28), the ceramide galactosyltransferase 
family (29), and the polypeptide GalNAc-transferase family 
(23). Analysis of the sequence similarities within these glyco­
syltransferase gene families reveals that conserved sequences 
are generally limited to short sequence stretches in the puta­
tive catalytic domains, which are located in the central or 
C-terminal portions of enzymes that are type II transmem­
brane proteins. An additional characteristic is that cysteine res­
idues in these areas are conserved in spacing (23, 30). Cysteine 
residues are important for intramolecular disulfide bonding as 
well as for the catalytic activity of glycosyltransferases (31-34),
1 The abbreviations used are: RT-PCR, reverse tr an scrip tion-po- 
lymerase chain reaction; EST, expressed sequence tags; bp, base pair(s); 
Cer, cer amide.
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The UDP-galactose:/3-N-acetylglucosamine /31,4-galactosyl- 
transferase (designated /34Gal-Tl; GenBank™/EMBL Data 
Bank accession number X14085) was the first glycosyltrans­
ferase to be isolated and cloned (3-5, 7, 35), and early searches 
for homologous genes by low stringency Southern hybridization 
suggested that this gene was unique. Characterization of /34-
Gal-transferase activities from different sources, however, in-
f
dicated that distinct activities exist (36, 37). Emerging evi­
dence now reveals that several jS4-galactosyltransferase genes 
may exist. Shaper et al. (38) have identified two different chick 
cDNA sequences, which have 65 and 48% sequence similarity 
to human j34Gal-Tl. Both chick cDNAs were shown to encode 
catalytically active /34-Gal-transferases. Thus, the j34Gal-Tl 
gene is likely to be part of a homologous gene family with 
recognizable sequence motifs, and this is supported by a large 
number of human ESTs with sequence similarities to j34Gal-Tl 
in EST data bases.2 Two independent groups have analyzed 
j34-Gal-transferase activities in mice liomozygously deficient in 
/34Gal-Tl (39, 40). Both studies showed residual j34-Gal-trans­
ferase activity, providing clear evidence for the existence of 
additional |34-Gal-transferases. Uehara and Muramatsu (41) 
have identified and cloned a mouse cDNA that was shown to 
encode a protein with low |34-galactosyltransferase activity 
when expressed in Escherichia coli. This putative /34-galacto- 
syltransferase exhibited little or no sequence similarity to 
|34Gal-Tl, indicating that the gene is unlikely to represent an 
evolutionarily related member of a galactosyltransferase fam­
ily. Since the gene was expressed in E. coli, it makes evaluation 
of the kinetic parameters uncertain as this expression system 
has been shown to be poor for glycosyltransferases (42).
In this study, we used available human EST sequence infor­
mation to identify novel genes homologous to |34Gal-Tl. The 
/34Gal-Tl gene was found to be highly represented in the EST 
data base by ESTs with nearly identical sequences, but in 
addition, a number of ESTs with similar sequences were iden­
tified, and these had shared motifs with conserved cysteine 
residues previously shown to be functionally important for 
/34Gal-TL The full coding sequences of two of these genes were 
established, and expression demonstrated that these genes 
represented active UDP-Gal:j3-GlcNAc /31,4-Gal-transferase 
genes.
EXPERIMENTAL PROCEDURES
Identification of Genes Homologous to $4Gal-Tl—Database searches 
were performed with the coding sequence of the human j34Gal-Tl 
sequence (43) using the BLASTn and tBLASTn algorithms against the 
dbEST data base at the NCBI. The BLASTn algorithm was used to 
identify ESTs representing the query gene (identities of >95%), 
whereas tBLASTn was used to identify non-identical, but similar EST 
sequences. ESTs with 50-90% nucleotide sequence identity were re­
garded as different from the query sequence. The results of tBLASTn 
searches were evaluated by visual inspection after elimination of ESTs 
regarded as identical to the query sequence (>95% nucleotide sequence 
identity). ESTs with several apparent short sequence motifs and cys­
teine residues arranged with similar spacing were selected for further 
sequence analysis. Initially, the identified ESTs (5'-sequence) were 
used in BLASTn searches of the dbEST data base to search for over­
lapping ESTs (95-100% identity in at least 30 bp) (see Fig. 1). If new 
ESTs were identified, the procedure was repeated, and sequences were 
merged. In addition, all identified ESTs were analyzed in the Unigene 
data base to confirm that they were from the same gene transcript and 
to select cDNA clones with the longest inserts as well as to identify 
additional ESTs with a non-overlapping 5'-sequence. Composites of all 
the sequence information for each set of ESTs were compiled and 
analyzed for sequence similarity to human j34Gal-Tl, EST cDNA clones 
with the longest inserts (see Fig. 1) were obtained from Genome 
Systems Inc.
Cloning and Sequencing of the Full Coding Sequence of $4Gal-T2—
2 R. Almeida and H. Clausen, unpublished observation.
Two partly overlapping ESTs were identified (see Fig. 1). Sequencing of 
the inserts revealed an open reading frame that potentially encoded a 
sequence similar to that of jS4Gal-Tl, but the 5'-sequence was shorter 
and without an initiation codon. Further 5'-sequence was obtained by 
5 '-rapid amplification of cDNA ends using human fetal brain Mara­
thon-Ready cDNA (CLONTECH) in combination with the antisense 
primers EBER102 (5' -GAAACTGAGCCTTACTCAGGC) and EBER104 
(5 '~TCCACATCGCTGAAGATGAAGC) for 35 cycles at 95 °C for 45 s, 
55 °C for 15 s, and 68 °C for 3 min using the Expand kit enzyme 
(Boehringer Mannheim). The products from the 5'-rapid amplification 
of cDNA ends were cloned into the BaniHl/Notl site of pT7T3U19, and 
multiple clones were sequenced. The entire sequence was confirmed by 
sequencing genomic P I clones. The composite sequence contained an 
open reading frame of 1191 bp potentially encoding a protein with a 
type II domain structure (see Fig. 2), with an overall sequence identity 
of —63% to j34Gal-Tl.
Cloning and Sequencing of the Full Coding Sequence of $4Gal-T3— 
One EST clone (184081) with a 1980-bp insert was identified by its 
3 '-EST sequence in Unigene (National Center for Biotechnology Infor­
mation) (see Fig. 1). Sequencing of the insert revealed an intact open 
reading frame of 1179 bp potentially encoding a protein with a type II 
domain structure (see Fig. 3), with an overall sequence identity of ~54% 
to /34Gal-Tl,
Expression of fi4Gal-T2 and $4Gal-T3 in Sf9 Cells—An expression 
construct designed to encode amino acid residues 56-397 of 04Gal-T2 
was prepared by RT-PCR with mRNA from the Colo205 ceil line using 
the primer pair EBERIOOFOR (5'-TACTTTGACGTCTACGCCCAG) 
and EBER114 (5' -GAAAAC AGAGCC C AGTC C AG) with BamHl restric­
tion sites (see Fig. 2). An expression construct designed to encode amino 
acid residues 23-393 of /34Gal-T3 was prepared by RT-PCR with RNA 
from the MKN45 gastric carcinoma cell line using the primer pair 
EBER2O0FOR (5'-CATGATGTACCTGTCACTGGGG) and EBER214 
(5 '-TAGCACGGCACCAGAGTTCAG) withSamHI restriction sites (see 
Fig. 3). The PCR products were cloned into the BamHl site of pAcGP67 
(Pharmingen), and the construct was sequenced to verify correct inser­
tion and sequence. A full-length coding expression construct of /34Gal> 
T3 was prepared by RT-PCR with MKN45 RNA using the primer pair 
EBER200FUL (5' -CCAGGATGTTGCGGAGGCTGC) and EBER214 
(see Fig. 3 ), and the product was cloned into the BamHl site of pVL1193 
(Pharmingen). Plasmids pAcGP67-/34Gal-T2-sol, pAcGP67-/34Gal-T3- 
sol, and pVL-)34Gal-T3-full were cotransfected with BaculoGold™ DNA 
(Pharmingen) as described previously (19). Recombinant baculovirus 
was obtained after two successive amplifications in Sf9 cells grown in 
serum-containing medium, and titers of virus were estimated by titra­
tion in 24-well plates with monitoring of enzyme activities. Controls 
included pAcGP67-GalNAc-T3-sol (19). Standard assays were per­
formed in 50 ¡A of total reaction mixture containing 25 mM Tris (pH 7.6), 
10 m M  MnCl2, 0.25% Triton X-100, 100 UDP-[14C]Gal (2300 cpmI 
nmol; Amersham Corp.), and varying concentrations of acceptor sub­
strates (Sigma) (see Table I for structures). The soluble constructs were 
assayed with 5-20 ¡j!  of culture supernatant from infected cells, 
whereas the full-length construct was assayed with 1% Triton X-100 
homogenates of washed cells. Bovine milk /31,4-Gal-transferase (Sig­
ma) was used as control. Assays used for determination of Km of 
acceptor substrates were modified to include 200 ¡jlu UDP-[14C]Gal, 
and assays for donor substrate Km were performed with 2 mM (for 
/34Gal-T3 and bovine milk Gal-transferase) or 0,25 mM (for /34Gal-T2) 
b enzyl - /3- GlcNAc.
Characterization of the Product Formed with ($4Gal-T3—Soluble 
j34Gal-T3 was partially purified by sequential DEAE and S-Sepharose 
chromatographies from serum-free medium as described previously 
(44). Terminal glycosylation of LcsCer (see Table III for definitions of 
Svennerholm nomenclature) was performed in a reaction mixture con­
sisting of 3 milliunits of /34Gal-T3 (specific activity determined with 
benzyl-j3-GlcNAc), 250 /xg of Lc3) 25 m M  Tris (pH 7.4), 10 m M  MnCl2,
0.25% Triton CF-54, and 3.5 ¡imol of UDP-Gal in a final volume of 100 
fil. The LcsCer substrate was prepared from sialosyllactoneotetraosyl- 
ceramide of bovine erythrocytes (45) by desialylation with 5% HAc in 
2-propanol/hexane/H20 (55:25:20, v/v/v; lower phase) at 80 °C for 4.5 h, 
isolation of the nLc4Cer product by passage through DEAE-Sephadox 
A-25 (Na+ form) in CHCl3/MeOH/H20 (30:60:8, v/v/v), and treatment of 
the product with jack bean |3-galactosidase as described previously (46, 
47). The Lc3Cer product was evaluated by high performance TLC and 
1H NMR (47). The glycosylation of Lc3Cer with /34Gal-T3 was monitored 
by high performance TLC and run for 24 h until completed. The crude 
reaction mixture was taken up in ~3 ml of 0.1 M NaCl, sonicated 
thoroughly, applied to a 1-ml disposable octadecylsilica cartridge 
(Bakerbond, J. T. Baker Inc.), washed through with 4 ml each of 0.1 M
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Bank accession numbers with available sequence lengths in parentheses, Vertical dashed lines labeled with numbers indicate 5'-positions of EST 
clones compared with the coding sequence of the gene. RACE, rapid amplification of cDNA ends.
NaCl and H20, and then eluted with 4-ml portions of H20 containing 
increasing amounts of MeOH from 10 to 90%, followed by 100% MeOH. 
Following concentration of each fraction, an assessment by high per­
formance TLC analysis showed that the glycosphingolipid product was 
eluted as a single band with 100% MeOH, whereas the detergent eluted 
at 80% MeOH. The purified product was deuterium-exchanged by dis­
solving in CDC13/CD30D (2:1), evaporating thoroughly under dry nitro­
gen (repeating twice), and then dissolving in 0.5 ml of Me2SO-ci6 and 2% 
D20 (48). One-dimensional :H NMR spectroscopy was performed on a 
Bruker AMX-500 spectrometer (temperature, 308 K; spectral width, 
5000 Hz acquired over 16,000 data points; relaxation delay, 2 s; and 
solvent suppression by presaturation pulse). NMR spectra of both the 
substrate and product were interpreted by reference to spectra of rele­
vant glycosphingolipid standards acquired previously under identical 
conditions (46, 47, 49).
Northern Analysis—Human multiple tissue Northern blots were ob­
tained from CLONTECH. The soluble expression construct of /34Gal-T2 
and the full coding construct of /34Gal-T3 were used as probes. Probes 
were random prime-labeled using [a-32PldCTP (Amersham Corp.) and 
an oligonucleotide labeling kit (Pharmacia Biotech Inc.). The blots were 
probed overnight at 42 °C as described previously (19) and washed 
twice for 10 min each at room temperature with 2 X SSC and 1% 
Na4P202; twice for 20 min each at 65 °C with 0.2 X SSC, 1% SDS, and 
1% Na4P20 2; and once for 10 min with 0.2 X SSC at room temperature.
Genomic Cloning and Characterization of the Organization of(Z4Gal- 
T2 and (54Gal-T3—A human foreskin genomic PI library (DuPont 
Merck Pharmaceutical Co. Human Foreskin Fibroblast PI Library) was 
screened using the primer pairs EBER100 (5' -TGAAGGAGGATGC- 
CGCCTATGAC) and EBER102 for /34Gal-T2 and EBER200 (5'-CCCT- 
GCGTGATGAAGAGTGGG) and EBER202 (5'-ATCTTC AGGT ACTG- 
GTCAGG) for /34Gal-T3. Three clones for /34Gal-T2 (DPMC-HFF10638: 
515:G9, DPMC-HFF10639:516:G4, and DPMC-HFF10640:924:A11) 
and three clones for j34Gal-T3 (DPMC-HFF1-0288-D2, DPMC-HFF1- 
0838-A8, and DPMC-HFF1-1486-H6) were obtained from Genome Sys­
tems Inc. DNA from PI phages was prepared as recommended by 
Genome Systems Inc. The entire coding sequence of each gene was 
sequenced in full using automated sequencing (AB1377, Perkin-Elmer) 
with dye terminator chemistry. Intron/exon boundaries were deter­
mined by comparison with the cDNA sequences optimizing for the gt/ag 
rule (50).
In Situ Hybridization to Metaphase Chromosomes—•Fluorescence in 
situ hybridization was performed on normal human lymphocyte met­
aphase chromosomes using essentially the procedures as described 
previously (51). Briefly, PI DNA was labeled withbiotin-14-dATP using
the bioNICK labeling system (Life Technologies, Inc.), The labeled DNA 
was precipitated with ethanol in the presence of herring sperm DNA, A 
total of 300 ng of P I DNA was precipitated with 50 x human Cotl DNA 
(Life Technologies, Inc.) and dissolved in 12 ml of hybridization solution 
(2 X SSC, 10% dextran sulfate, 1% Tween 20, and 50% formamide (pi I 
7.0)). Prior to hybridization, the probe was heat-denatured at 80 °C for 
10 min, chilled on ice, and incubated at 37 °C to allow re-annealing of 
highly repetitive sequences. After denaturation of the slides, probe 
incubations were carried out under a 18 X 18-mm coverslip in a moist, 
chamber for 45 h. Immunochemical detection of the probe was achieved 
using fluorescein isothiocyanate-labeled avidin (Vector Laboratories 
Inc.) and several successive steps with rabbit anti-fluorescein isothio- 
cyanate- and mouse anti-rabbit fluorescein isothiocyanate-conjugated 
antibodies. For evaluation of the chromosomal slides, a Zeiss epifluo* 
rescence microscope equipped with appropriate filters for visualization 
of fluorescein isothiocyanate was used. Hybridization signals and 4,6- 
diamidino-2-phenylindole-counterstained chromosomes were trans­
formed into pseudo-colored images using image analysis software. For 
precise localization and chromosome identification, 4,6-diamidino-2- 
phenylindoie-converted banding patterns were generated using tho 
BDS-image™ software package (ONCOR).
RESULTS
Identification and Cloning of Human [$4Gal-T2 a?id ¡34Gal~ 
T3—The strategy outlined in Fig. 1 produced two novel genen 
with significant sequence similarity to /34Gal-Tl (Figs. 2 and 
3). Additionally, two genes with significant similarities in the 
3'-region were identified (data not shown). Multiple sequence 
alignment analysis of /34Gal-Tl, the two novel human /34Gal-T 
enzymes, two homologous sequences from chick (38), and a 
snail 04GlcNAc-transferase (52) is shown in Fig. 4. The /34Gal- 
T1 gene shows high sequence similarity (65%) throughout tho 
coding region to one of the chick genes (GenBank'™/EMBL 
Data Bank accession number U19890), and /34Gal-T2 show« 
high similarity (72%) to the second chick gene (GenBank™/ 
EMBL Data Bank accession number U19889), suggesting that 
these may represent species-associated members of related 
gene families. The amino acid sequence similarities among the 
three human /34-Gal-transferases and the snail /34GlcNAc- 
transferase are limited to the central regions; there were no 
significant similarities in the NH2~ terminal regions. Human
P4Gal-T2
_g3 ...............................................................AGCC TGG T CCCAGTTGG CCTG CCCTG CT TGT CGCTGGGATCTGAATGACCAAACCACTT C C CAC CAT GGCT C CTGGAAGGACTAAATGAAGTC - l
1 m s i k c s c m a s s r m p g p t g r a s g r l r d e q t a g g t l e r  V . C K____ A 40
1 ATGAGTATAAAGTGCTCCTGCATGGCCAGCAGCCGGATGCCCGGGCCCACTGGGCGGGCCAGTGGCCGCrrGCGGGATGAGCAGACTGCTGGGGGGACGCTGGAGCGCGTCTGOAAGGCT 120
41 V L . I . L C L L H  F L V A V  I  L Y F D V Y A Q H L A F F S R F S A R G P A H A L H  BO
12i  p^flr^rr^TrrrTrirrTr;rTnrarTTrPTrnTnr,gC!GTgATCCTC!TAC^rGACGTCTACGCCCAGCACCTGGCCTTCTTCAGCCGCTTCAGTGCCCGAGGCCCTGCCCATGCCCTCCAC 240
81 P A A S S S S S S S N * C S R P N * A T A S  S S G L  P E V P S A L  P G P T A P T L P  120
241 CCAGCTGCTAGCAGCAGCAGCAGCAGCAGCAACTGCTCCCGGCCCAACGCCACCGCCTCTAGCTCCGGGCTCCCTGAGGTCCCCAGTGCCCTG CCCGGTCCCACGGCTCCCACGCTGCCA 360
121 P C P D S P P G L V G R L L I  E P T S  P M P L B  R V Q R E N P G V L M G G R Y T  160
361 C CCTGT CCTGACTCG C CACCTGGTCTTGTG GG CAGACTGCTGAT CGAGT T CAC CTCACCCATGC C CCTGGAG CGGGTG CAGAGGGAG AACCCAGGCGTG C T CATGGG CGG CCG ATACACA 480
161 P P D C T P A Q T V A V I I P F R H R E H H L R Y W L H Y L H P I L R R Q R L R  200
4 81 CCGCCCGACTGCAC CCCAGCCCAG ACGGTGG CGGTCAT CAT CCCC TTT AG ACACCGGG AACACCAC CTGCG CTA CTGGC TCCACT AT CTACACC CCATCTTGAGGCGG CAGCGG CTG CGC 600
201 Y G V Y V I N Q H G E D T F N R A K L L N V G F  L E A L K E D  A A Y D C F  I  F S 240
601 TACGGCGTCTATGT CATCAACCAGCATGGTGAGGACACCTTCAACCGGGCCAAGCTGCTTAACGTGGGCTTCCTAGAGGCGCTGAAGGAGGATGCCGCCTATGACTGCTTCATCTTCAGC 720
241 D V D L V P M D D R N L Y  R C G D Q  P R  H F A I  A M D K F G F R L P Y A G Y F G  280
721 GATGTGGACCTGGTCCCCATGGATGACCGCAACC TATACCGCTGCGGCGACCAACCCCGCCACTTTGCCATTGCCATGGACAAGTTTGGCTTCCGGCTTCCCTATGCTGGCTACTTTGGA 840
281 G V S G L S K A Q F L R X N G F P N E Y W G W G G E D D D X F N R I S l i T G M K  320
841 GGTGTGTCAGGCCTGAGTAAGGCTCAGTTTCTGAGAAT CAAT GG CTT CC CCAATGAGTACTG GGG CTG GGGTGGCG AGG AT GATGACAT CTTCAAC CGG AT CT CCCTG ACTGGGATGAAG 960
321 I S R P D I R I G R Y R M I K H D R O K H N E P N P Q R F T K  I Q N T K L T M K  360
961 ATCTCACGCCCAGACATCCGAATCGGCCGCTACCGCATGAT CAAGCACGAC CG CGAC AAGCATAACGAACCTAA CC CT CAGAGGTTTAC CAAG ATTCAAAACACG AAG CTG AC CATG AAG 1080
361 R D G I G S V R Y Q V L  E V S R Q P L F T N ’ I T V D I G R P P S W P P R G *  397
1081 CGGGACGG CATTGGGT CAGTG CGGTAC CAGGTCTTGG AGGTGTCT CGGCAACCACT CTT CAC CAATATCACAGT GGACATTGGG CGG C CTC CGT CGTGG C C C CC TCGGGG CTG ACACTAA 1200
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1201 RfiRTTri C. ClTQr.ClAGAdC! ACTGAC.CACAGCCTGC CTGG CAGCTG CTCTGTGGAGGACCT C CAGG ACTG AGACTGGG CTC TGTTT TC CAAGGGT CTTCA 13 20
1321 CTAGG C CCCCTAG CT AC AC CTGGAAGTTTCAGAACC CAC T TTGGGGGG CC TCCTG CCTGGGCAGG CTCTT CAAGT GTGGCCCTCTTT GGAGTCAAC CCTCCTTC CCGAC CCCCTCCCCCT 14 40
1441 AG CCCAGCCCCAGTCACTG TCAGGGTCGGG CCAG CCCCTGCACTGCCTCG CAGAGTGGC CTGGGC TAGGTCA CTCCACCTCTCTGTGCCT CAGTT TC C CCC CCTTGAGTCC CCTAGGG C C 15 60
15 61 TG GAAGGGTG G GAGGTATGTCTAGGGGG CAGTGT C TCTT CCAGGGGGAATTCTCAG CTCTTGGGAAC CCCCTTGCTCC CAGGGGAGGGGAAAC CTTTTTCAT TC AACAT TGTAGGG GG CA 16 8 0
1681 AGCTTTGGTG CG C C C CCTGCTG AGG AGCAGCCCC AGGAGGGG ACCAG AGGGG ATG CTGTGTCG CTGCC TGGGATCTTGGGGTTGGCCTTTG CATGGG AGG CAGGTGGGGC TTGGATC AGT 1800
1801 AAGTTTGGTTCCCGCCTCCCTGTTTGAGAGAGGAGGCAGGAGCCCCAGGGCCGGCTTGTGTTTGTACATTGCACAGAAACTTGTGTGGGTGCTTTAGTAAAAAACGTGAATGGAAAAAAA 1520
1921 AAAAAAAAAAAAA 1933
Fig. 2. Nucleotide sequence and predicted amino acid sequence of human 04GaI-T2, The amino acid sequence is shown in single-letter 
code. The hydrophobic segment representing the putative transmembrane domain is double-underlined (Kyte and Doolittle (85), window of 8K 
Three potential N-glycosylation sites are indicated by asterisks. The locations of the primers used for RT-PCR preparation of the expression 
construct are single-underlined.
p4Gal-T3
-94 -1
1 M L R R L L E R P C T L A L L V G S O L A V M M Y L S L G G F R S L S A I i F G R 40
1 ATGTTGCGGAGGCTGCTGGAGCGGCCTTGCACGCTGGCCCTGCTTGTGGGCTCCCAGCTGGCTGTCATGATGTACCrGTCACTGGGGGGCTTCCGAAGTCTCAGTGCCCTATTTGGCCGA 120
41 D q g p t f d y s h p r d v y s n ' l s  h l p g a p g g p  P A P  Q G L P Y C  P E R 80
121 GATCAGGGACCGACATTTGACTATTCTCACCCTCGTGATGTCTACAGTAACCTCAGTCACCTGCCTGGGGCCCCAGGGGGTCCTCCAGCTCCTCAAGGTCTGCCCTACTGTCCAGAACGA 240
81 s P L L V G P V S V S F S  p v  p s l a e  x v e r w p r v  E P G G R Y R P A G C E 120
241 TCTCCTCTCTTAGTGGGTCCTGTGTCGGTGTCCTTTAGCCCAGTGCCAT CACTGG CAGAG ATTG TGGAG CGGAATCC CCGGGTAGAACC AGGGGGC CGGTAC CGCCCTGCAGGT TGTGAG 350
121 P R S R T A I I V P H R A R E H H I i R L & L Y H L H P F L Q R Q Q L A Y G I Y V  160
361 CCCCG CTCCCGAACAGCCATCATTGTGCCTCATCGTGCCCGGGAG CACCACCTG CGCCTG CTGCTCTACCAC CTGCACCCCTTCTTGCAGCGCCAGCAGCTTGCTTATGGCATCTATGTC 480
161 I H Q A G N ' G T F  N R A K L L N V G V R E A L R D E E W D C L F L H D V D L L P  200
481 ATCCACCAGGCTGGAAATGGAACATTTAACAGGGCAAAACTGTTGAACGTTGGGGTGCGAGAGGCCCTGCGTGATGAAGAGTGGGACTGCCTGTTCTTGCACGATGTGGACCTCTTG CCA 500
201 E N D H N E < Y V C j D P R G P  R H V A V A M N K P G Y  S L  P Y  P Q Y  F G G V S A  L 240
601 GAAAATGAC CACAATCTGTATGT GTGTG AC C CC CGG GGACCC CGCCATGTTGCCGTTGC TATGAAC AAGTTTGG ATACAG CCT C C CGTAC CCC CAGTACTTCGG AGGAGTCTCAG CACTT 720
241 T P D Q Y L K M N G F P N E Y W G W G G E D D D  I A T R  V R L A G M K I  S R P  P 290
721 ACTCCTGACCAGTACCTGAAGATGAATGGCTTCCCCAATGAATACTGGGGCTGGGGTGGTGAGGATGACGACATTGCTACCAGGGTGCGCCTGGCTGGGATGAAGATCTCTCGGCCCCCC 840
281 T S V G H Y K M V K H R G D  K G N E E N P K R F  D L L V  R T  Q N S  W T Q D G M N  320
841 ACATCTGTAGGACACTATAAGATGGTGAAGCACCGAGGAGATAAGGGCAATGAGGAAAATCCC CACAGATTTGACCTCCTGGTCCGTACCCAGAATTCCTGGACGCAAGATGGGATGAAC 960
321 S L T Y Q L L A R E L G P L Y T N ‘ I T A D I G T D P R G P R A P S G P R Y P P G  360
961 T CACTGA CATAC CAGTTG CTG G CT CGAGAG CTGGGGC CTCTT TATACCAACATCACAG C AGACATTGGGACT GAC C CTCGGGGTCCTCGGGCTCCTTCTGGGCCACGTTACCCACCTGGT 1080
361 S S Q A F R Q E M L Q R R P  P A R P G  P L i S T A N * H T A L R G S H  * 3.93
1081 TCCTCCCAAGCCTTCCGTCAAGAGATGCTGCAACGCCGGCCCCCAGCCAGGCCTGGGCCTCTATCTACTGCCAACCACACAGCCCTCCGAGGTTCACACTGACTCCTCCTTCCTGTCTAC 1200
1201 CTTAAT CATGAAACCGAATT CATGGGGTTGTATTCT C CCCA CCCTCAG CTCC T CACTGTTCT CAG AGG GAT GTG AG GG AACTG AACTCTGGT GCCGTGCTRGGGGGTAGGGGCCTCTCCC 1320
1321 TCACTG CTGGACTGGAGC TGGGCTCCTGTAGAC CTG AGGGG TCCC TCTCTCTAGGGTCTC CTGTAGGGCTTATG ACTGTGAATCCTTGATGT CATGAT TTTATGTG ACG ATTCCTAGGAG 1440
1441 TCCCTGCCCCTAGAG rAGGAGCAGGGCTGGACCCCAAGCCCCTCCCTCTTCCATGGAGAGAAGAGTGATCTGGCTTC TCCTCGGACCTCTGTGAATATTTATTCTATTTATGGTTCCCGG 156 0
1561 GAAGTT GTTTGGTGAAGG AAGCCCCTC CCCTGGG CAT TTTCTGCC TATGCTGG AATAGCT CCCTCTT CTGGT CCTGG CTCAGGGGG CTGGG AT T TTG AT AT AT T TT CT AATAAAGG ACTT 1680
1681 TGTCTCGCAAAAAAAAAAAAAAAAAA 1706
Fig. 3. Nucleotide sequence and predicted amino acid sequence of human |34Gal-T3. Designations are as described in the legend to Fig.
2 . A potential polyadenylation signal is indicated in boldface underlined type.
/34Gal-Tl is closest in sequence to human jS4Gal-T2 (52% iden- Several sequence motifs in the putative catalytic domains are 
tity), more distant from human /34Gal-T3 (44% identity), and conserved among all the sequences. More important, four cys- 
most distant from snail jS4“GlcNAc-transferase (34% identity), teine residues are conserved in all coding sequences (Fig. 4).
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Fig. 4. M ultiple sequence analysis (ClustalW) of human /34Gal-TX, )34Gal-T2, and /34Gal-T3; two chick sequences; and the snail 
/34-GlcNAc-transferase. Introduced gaps are shown as dashes, and aligned identical residues are boxed (black for all sequences, dark gray for 
five sequences, and light gray for four sequences). $4GlcNAcT} f34-GlcNAc-transferase.
i
The predicted coding region of j34Gal-T2 has three potential 
initiation codons, and the most 5' is in agreement with Kozak's 
rule (53) (Fig. 3). All three initiation codons are relatively far 
from the sequence encoding the transmembrane segment: 25, 
30, and 37 residues, respectively. The predicted coding se­
quence depicts a type II transmembrane glycoprotein with 
three potentially different long N-terminal cytoplasmic do­
mains, a transmembrane segment of 21 residues, and a stem 
region and catalytic domain of 339 residues, with three poten­
tial N-linked glycosylation sites (Fig. 2). A 3'-untranslated 
region without poly adénylation signals was included in the 
oligo(dT)-primed EST cDNA clones sequenced. The 3'-ESTs 
(STsG4681) were linked to chromosome 1 between D1S2861 
and D1S211 micro satellite markers at 73-75 centim organs 
(National Center for Biotechnology Information).
The predicted coding region of j34Gal-T3 has a single initia­
tion codon, in agreement with Kozak’s rule (53), placed imme­
diately before a sequence encoding a potential hydrophobic 
transmembrane segment (Fig. 3). The predicted coding se­
quence yields a type II transmembrane glycoprotein with an 
N-terminal cytoplasmic domain of four residues, a transmem- 
brane segment of 18 residues, and a stem region and catalytic 
domain of 371 residues, with four potential N-linked glyco­
sylation sites. A 37-untranslated region with a polyadenylation
signal at position +486 was included in the EST clones se­
quenced. The 3'-ESTs (STsG2055) were linked to chromo­
some 1 between D1S484 and D1S426 microsatellite markers 
at 173-181 centimorgans (National Center for Biotechnology 
Information).
Expression off34Gal-T2—Expression of a soluble construct of 
j34Gal-T2 in Sf9 cells resulted in a marked increase in galac- 
tosyltransferase activity using the benzyl-/3-GlcNAc acceptor 
substrate compared with uninfected cells or cells infected with 
control constructs for polypeptide GalNAc-transferases or 
histo-blood group A and O genes (Table I) (19, 54). Analysis of 
the substrate specificity of the soluble /34Gal-T2 activity 
showed that only benzyl-/3-GlcNAc, and not benzyl-a-GlcNAc or 
benzyl-a-GalNAc, was an acceptor substrate. Free glucose was 
not an acceptor, but in the presence of increasing concentra­
tions of a-lactalbumin, incorporation rates similar to those for 
bovine milk /34-Gal-transferase were observed (Pig, 5A). Differ­
ences in the concentration of a-lactalbumin needed to achieve 
maximum activity with Glc were observed, with 400 /xg/ml 
required for )34Gal-T2 and only 100 ¡xg/ml for the bovine milk 
enzyme. The activities of both /34Gal-T2 and the bovine milk 
enzyme with GlcNAc were inhibited by a-lactalbumin, but 
/34Gal-Tl was overall more sensitive to inhibition (Fig. 55). 
The apparent Km for benzyl-/3-GlcNAc was 160 /llm, and the Km
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Table I
Substrate specificity of ß4-Gal-transferases
Substrate concentration
ß4Gal-T2a ß4Gal-T3° Bovine j34-Gal-transferase0
1 m M 3 mM 9 mM 1 mM 3 mw 9 mM 1 mM 3 mM 9 im r
nmolJminhnl nmol/min/ml nmol/min/ml
D-GlcNAc 1.4 3.2 4.8 2.3 4.5 9.4 63 150 286
Bzl-ß'ü-GlcNAc6 6.8 3.6 1.5 16.1 13.9 5.6 411 407 232
Bzl-a-D-GlcNAc 0.4 1.1 1.7 0.4 1.3 1.9 0.0 15 30
o-Nph-a-D-GlcNAc 0.4 0.8 1.5 0.3 1.2 1.0 0.0 0.0 48
p-Nph-ß-D-GlcNAc 3.0 2.3 0.9 11.8 12.5 6,5 188 380 226
p-Nph-1-thio-ß-D-GlcNAc 1.2 1.6 0.2 9.9 6.9 2.1 140 236 160
4-Me-lumb-/3-0-GlcNAc 0.8 0.6 0.4 7.9 3.8 3.3 213 198 159
ß-D-GlcNAc-(l-3)-ß-D-Gal-l-OMe 5,8 7.7 ND 7.8 15.1 ND 246 350 ND
ß-D-GlcNAc-(l“-6)-a-D-Man-l~OMe 8.5 11.3 ND 12.7 20,4 ND 441 523 ND
B zl-2-( 2- ß -d - GlcNAc)-a-D-GlcNAc 9.9 2.6 1.3 13.0 7.0 1.4 535 288 140
4-Me4umb * ß-D-GalNAc ND 0.0 ND ND 0,0 ND ND 0.0 ND
o-Nph-ß-D-GalNAc ND 0.0 ND ND 0.0 ND ND 0.0 ND
Bzl-a-D-GalNAc ND 0.0 ND ND 0.0 ND ND 0.0 ND
4-Me-lumb-ß-D-Gal ND 0.0 ND ND 0.0 ND ND 0.0 ND
o-Nph-ß-D-Gal ND 0.0 ND ND 0.0 ND ND 0.0 ND
a Enzyme sources were media of infected Sf9 cells, 
construct were subtracted. The background rates were 
* Bzl, benzyl; Nph, nitrophenyl; lumb, lumbelyl; ND,
Background values 
not higher than 0.5 
not determined.
obtained with uninfected cells 
nmol/min/ml.
or cells infected with an ixrelevant
Pig. 5. a>Lactalbumin modulation 
of 4-galactosyl transferase activi­
ties.^, activities with glucose in the pres­
ence of increasing amounts of a-lactalbu- 
min. The results are presented relative to 
the activities obtained with 40 mM glu­
cose. 5, activities with GlcNAc in the 
presence of increasing amounts of a-lac- 
talbumin. The results are presented rela­
tive to the activities obtained with 2 m M  
(for the bovine milk enzyme and 04Gal- 
T3) or 0.25 m M  (for /34Gal-T2) benzyl-j3- 
GlcNAc (Bz-fi-GlcNAc). Purified bovine 
milk enzyme or medium from Sf9 cells 
expressing secreted forms of either 
£4Gal-T2 or /34Gal-T3 was used as the 
enzyme source. A, bovine milk Gal-trans­
ferase; ■, /34Gal-T2; ,34Gai-T3.
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for UDP-Gal using benzyl-/3-GlcNAc was 11 ¡jlm  (Table II). 
Bovine milk /34-galactosyltransferase showed higher a Km for 
UDP-Gal, in agreement with previous studies (37, 55-58), and 
the measured Km for GlcNAc was similar to that determined in 
some studies (59, 60), but 5-10-fold higher compared with 
other studies (55-58). As shown in Fig. 6, j34Gal-T2 was inhib­
ited at high concentrations of both benzyl-jS-GlcNAc and free 
JV-acetylglucos amine to a higher degree than bovine milk J34-
Gal-transferase and /34Gal-T3 (61). /34Gal-T2 showed strict 
donor substrate specificity for UDP-Gal and did not utilize 
UDP-GalNAc or UDP-GlcNAc with the acceptor substrates 
tested (data not shown).
Expression of fi4Gal-T3—Expression of the soluble construct 
of /34Gal-T3 in Sf9 cells produced a marked increase in Gal- 
transferase activities with the benzyl-jS-GlcNAc acceptor sub­
strate compared with uninfected cells or cells infected with the
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control construct for GalNAc-T3 (Table I). A similar increase in 
activity was found in Sf9 cell homogen at es after expression of 
the full-length construct of j34Gal-T3 (data not shown). The 
substrate specificity was similar to that of ]34Gal-T2. j34Gal-T3 
was largely insensitive to a-lactalbumin and did not efficiently 
utilize glucose (Fig. 5). The apparent Km for benzyl-/3-GlcNAc 
was 580 fjM, and the Km for UDP-Gal using benzyl-/3-GlcNAc 
was 84 fxM (Table II). jS4Gal-T3 showed strict donor substrate 
specificity for UDP-Gal. Analysis of the specificity of /34Gal-T3 
with glycolipid substrates revealed that Lc3Cer was efficiently 
utilized, whereas Glcj31-Cer and nLc5Cer were poor substrates 
(Table III). This was in contrast to the activities found with the 
bovine milk /34-Gal-transferase that efficiently utilized both 
Lc3Cer and nLc5Cer.
Structural characterization of the product formed with 
LcgCer by XH NMR showed that j34Gal-T3 forms the same 
linkage as j34Gal-Tl. One-dimensional 1H NMR spectroscopy 
showed that the product was a single glycosphingolipid with a
Table II
Kinetic properties of $4-Gal~transferases
Substrate
ß4Gal-T2 04Gal-T3 Bovine /34-Gal 
transferase
K,m max Km v.max K,in v,max
UDP-Gal
Bzl-j3-D-GlcNAca
D-GlcNAc
mM
0.011
0.16
2.65
pinoli min
51.9
88.0
59.4
mM
0.084
0.58
13.1
pmollmin
128.7 
112.5
121.7
mM
0.034
0.53
9.6
p mal / m in
146.0
88.2
113.6
a Bzl, benzyl.
spectrum virtually identical to that of nLc4Cer acquired previ­
ously under identical conditions (49) and distinct from that of 
Lc4Cer (46). In the downfield region of the spectrum (Fig. 7), 
four distinct j3-anomeric resonances (3c712 = 7-9 Hz) were 
observed at chemical shifts of 4.169 ppm (3J i i2 ~ 7.4 Hz), 4.212 
ppm (3J 1>2 = 7.7 Hz), 4.263 ppm (3e/lj2 = 6.8 Hz), and 4.663 ppm 
(3J 12 = 8.3 Hz). These were all within ±0.004 ppm of those 
previously observed (71) for 1-1, IV-1, II-1, and III-l, respec­
tively, of nLc4Cer and thus clearly consistent with a /31-4 
linkage of the terminal Gal residue. Under these conditions, 
the resonance for H-l of the terminal Galj31-3 of Lc4Cer is 
found at 4.140 ppm (3J i )2 = 7.3 Hz), whereas that of the 
|3-GlcNAc III-l to which it is linked is found at 4.780 ppm 
(3J 1j2 = 7.9 Hz) (46).
Northern Analysis of ¡34Gal~T2 and j34Gal-T3—Northern 
analysis with mRNA from 16 human adult organs showed a 
single transcript of both genes of ~2.2 kb (Fig. 8). /34Gal-T2 
was expressed weakly in several adult organs, with the highest 
expression in prostate, testis, ovary, intestine, and muscle. 
|34Gal~T3 appeared to be more strongly expressed than /34Gal- 
T2, but with a similar pattern, with the exception of placenta, 
where strong expression of T3 was also found.
Genomic Organization and Chromosomal Localizations— 
The coding regions of /34Gal-T2 and |34Gal-T3 were found in 
seven and six exons, respectively (Fig. 9). Human |34Gal-Tl 
and mouse /34Gal-Tl are encoded in six exons (62, 63). The first 
putative coding exon of /34Gal-T2 encodes the first potential 
initiation codon and only eight amino acid residues of the 
N-terminal sequence of the longest form (Fig. 9), and it is
F ig . 6. Differential inh ib ition of 04- 
Gal-transferase activities by high ac­
ceptor substrate concentrations. A,
benzyl-j3-GlcNAc; B, GlcNAc* A, bovine 
milk Gal-transferase; ■, j34Gal-T2; • , 
/34Gal-T3. Bz /3~GlcNAc, benzyl-/3-Glc­
NAc.
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Table I I I
Substrate specificities with glycolipid acceptors
Acceptor substrate ß4Gal-T3“
GlcCer (Glcj31-Cer)
LacCer (Gal/3 l-4Glc/31-Cer)
Gb3 (Galal-4Galßl-4Glcßl-Cer)
Gb4 (GalNAcßl-3Galal-4Galj31-4Glcj31-Cer)
Gg3 (GalNAcj31-4Galj31-4Glcj31-Cer)
CMS (GalNAc/31-4(NeuAca2-3)Gal/3l-4Glc/31-Cer)
GM1 (Galßl-3GalNAcßl-4(NeuAca2-3)Galßl-4Glcßl-Cer)
L c 3 (GlcNAcßl-3GaIßl-4Glcßl-Cer)
nLc4 (Galßl-4GlcNAcßl-3Galßl~4Glcßl-Cer)
nLc5 (Gl cNAc ß 1-3 Galß l-4GlcNAc/31-3 Galß l-4Glcj31- C er)
nmol i h i ml
0.38
KDd
ND
ND
ND
ND
ND
9,7
ND
0.93
Bovine milk /34-Gal-transferase6
nmol Ih I mg
40.3(ND)C 
ND 
ND 
ND 
ND 
ND 
ND 
297 (386)*
ND 
333 (58)c
° Assayed using 100 ¡xg of Triton CF-54/100-jwl reaction mixture (enzyme source medium from in 
b Assayed using 100 jtxg of taurodeoxycholate/100-jid of reaction mixture (enzyme source, Sigma). 
r Assayed using 100 ¡ig of Triton CF-54/100 ¡A of reaction mixture. 
d ND, not detectable.
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Fig. 7. Downfield region of 500-MHz 1H NMR spectrum of glycosphingolipid produced by enzymatic glycosylation of Lc3Cer with 
(34GaI-T3. The product isolated by Sep-Pack C18 chromatography was deuterium-exchanged and dissolved in Me2SO-c£G and 2% D20. 2048 free 
induction decays were accumulated at 308 K. Arabic numbers refer to ring protons of residues designated by Roman numerals or upper-casc letters 
in the corresponding structure, R refers to protons of the sphingosine backbone.
possible that the most 5'-initiation codon is not used. An intron 
in the 5'-untranslated region of /34Gal-T3 was found in a sim­
ilar position as the most 5'-intron in (34Gal-T2 (Fig. 10). Com­
parison of the intron/exon boundaries of /34Gal-Tl, j84Gal-T2, 
and j34Gal-T3 revealed that the live introns in the coding 
regions of the three genes are placed identically (Fig. 10). The 
central coding exons of all three genes are of nearly identical 
length, and variation in lengths of coding regions may be at­
tributable to different initiation and stop codons in the first and 
last coding exons.
Human /34Gal-Tl was previously localized to chromosome 
9pl3 (64). The j34Gal-T2 and j34Gal-T3 genes were localized to 
chromosomes lp32-33 and lq23 by fluorescence in situ hybrid­
ization (Fig. 11). Nearly identical localizations were obtained 
from the EST mapping. No specific hybridization signals were
observed at other chromosomal sites, For each gene, a total of 
20 cells in metaphase were analyzed.
DISCUSSION
The data presented here demonstrate that the human 
/34Gal-Tl gene is a member of a large family of homologous 
glycosyltransferase genes and that at least three of the mem­
bers of this family, j34Gal~Tl, /34Gal-T2, and jS4Gal-T3, encode 
jBl,4-galactosyltransferases with similar kinetic parameters. 
The EST strategy used in this study has successfully been 
applied to other homologous gene families (22, 23, 65). The 
short sequence information of ~200—400 bp obtained from a 
single EST, which may contain sequencing artifacts, may not 
be considered strong evidence for a particular gene sequence of 
interest, However, in our experience, the reliability of EST
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sequences is very high, and the finding of similar protein se­
quence motifs and conserved cysteine residues similar to those 
of the query sequence strongly indicates the identification of a 
novel homologous gene. The establishment of the Unigene data 
base further confirms this by identifying other ESTs from the 
same gene from which more sequence can be compiled by direct 
comparison of sequences or with available insert sizes of ESTs. 
Thus, with the two genes identified in this study, most of the 
coding region can be identified from merged EST sequences, 
and a more detailed assessment of the authenticity of the 
putative homologous gene can be made. One drawback of the 
EST cloning strategy is that genes with long 3'-untranslated 
sequences may not be represented, and this has been a feature 
associated with some glycosyltransferase genes (8, 10, 66). A 
strong point of the EST strategy is that it offers access to 
expressed sequences from many different adult and fetal tis­
sues, leading to the possibility of identifying genes with very 
restricted expression patterns.
Some evidence suggested that j84Gal-Tl was a member of a 
homologous gene family. One distant member of this family 
was found to use UDP-GlcNAc and not UDP-Gal (52), indicat­
ing that members may have different donor substrate specific­
ities and functions. Interestingly, UDP-Gal;/3-GlcNAc /31,3- 
galactosyltransferases have no sequence similarity with 
/34Gal-Tl (GenBank™/EMBL Data Bank Accession number 
E07739).3 Several features of the two identified genes sug­
gested that they represented genuine glycosyltransferase 
genes. The genes had higher sequence similarities to /34Gal-Tl
3 M. Amado and H. Clausen, manuscript in preparation.
than to a homologous /34-GlcNAc-transferase from snail (52). 
Four cysteine residues were conserved in all sequences, and 
these have been, found to be involved in intramolecular disul­
fide bonding and catalysis for /34Gal-Tl (31, 32). Finally, the 
genomic organizations of both genes were shown to be identical 
to that of /34Gal-Tl, with the positions of five intron/exon 
boundaries conserved (Fig. 10). The last finding strongly sug­
gests that this gene family arose through complete gene dupli­
cation late in evolution. Furthermore, the genomic organiza­
tion of the homologous snail /34-GlcNAc-transferase gene was 
recently shown to be organized similarly, with conservation of 
the same five intron positions, but additionally, two exons were 
found as well (Fig. 10) (67). More important, the two chick 
j34-Gal-transferases identified by Shaper et al. (38) were also 
found to have genomic organizations identical to that of the 
/34Gal~Tl gene. The three /34-Gal-transferase genes have dif­
ferent chromosomal locations (64). Several large glycosyltrans­
ferase gene families have now been found to have different 
chromosomal locations (23, 24), but some are also clustered in 
one region (26, 28, 66).
The ]34Gal-Tl gene is different from most other known gly­
cosyltransferase genes in having two translational initiation 
sites controlled by two different promoters (35, 68). The two 
isoforms of /34Gal-Tl differ by having a short (11 residues) or 
long (24 residues) cytoplasmic sequence, and studies indicate 
that the short form primarily localizes to the Golgi apparatus 
and the long form primarily to the cell membrane (69). A 
number of biological roles have been attributed to a cell mem­
brane form of /34Gal-Tl (70). The |34Gal-T2 gene, showing the 
highest similarity to /34Gal-Tl, also resembles /34Gal-Tl in
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34Gal-T2
Fig. 9. Intron junctions in  the cod­
ing regions of the /34Gal-T2 and 
j34Gal-T3 genes. Exon sequences are 
shown in uppei'-case letters, with the nu­
cleotide positions from the initiation 
codon in subscript and the predicted 
amino acid sequence in single-letter code 
above the sequence. Flanking intron se­
quences are shown in lower-case letters, 
and introns are labeled according to Fig.
1. Sequences were aligned to the best fit of 
the gt/ag consensus rule.
S C M Intron 1 A S S
C TCC TGC ATG24 g ta g g tg c a c  c c g tg c tc a g  GCC AGO AGC C
P G L Intron2 V G R L
CCT GGT CTT G3B8 g tg a g c c tg g .  c tg tc tg c a g  TG GGC AGA CT
I  N Q Intron3 H G E
C ATC AAC CAG624 g tg c c c a tg c  c c c ta c c c a g  CAT GGT GAG G
F G F R Intron4 L P Y
TT GGC TTC CG815 g tg a g g g c tc  c a tg c c a c a g  G CTT CCC TAT
I  F N R IntronS I S L
TC TTC AAC CG93B g tg a g ta a g c  c c a tc c tc a g  G ATC TCC CTG
N p Q R Intronò F T K
AC CCT CAG AGlou g tg a c c c c a g  t c c t a t c t a g  G TTT ACC AAG
p4GaI-T3
Introni
TTG AAC CTA G_34 g t g a g t c t a t  c ta c c c c c a g  AA TTC CCC TC
P L  L Intron 2 V L P V
CCT CTC TTA G3S3 g ta a g tg c a g  t tc c c a a c a g  TG GGT CCT GT
I  H Q Intnon3 A G N
C ATC CAC CAG4B9 g ta c c c c c a a  t a t c t t c c a g  GCT GGA AAT G
F G Y S In1ron4 L P Y
TT GGA TAC AGSB0 g ta c a g g g c a  tc tc c c tc a g  C CTC CCG TAC
I A T R Intron5 V R L
TT GCT ACC AGfl03 g t c a g a c t t c  t t t c c c a t a g  G GTG CGC CTG
N P H R Intron 6 F D L
AT CCC CAC AG90g g ta g g a a g a a  ta a c c c tc a g  A TTT GAC CTC
having three initiation codons, potentially yielding isoforms 
with 25-, 30-, or 37-residue cytoplasmic sequences. A sequence 
motif (L(E/Q)RXC) is found in the cytoplasmic sequences of the 
human and chick genes immediately preceding the hydropho­
bic putative transmembrane signal sequence (Fig. 4), Since the 
major parts of the N-terminal regions of these genes show little 
or no sequence similarities, this conserved motif may be impor­
tant. Bendiak et al. (71) have shown that the j34-Gal-transfer­
ase appears to exist as a high molecular weight aggregate, and 
this motif could potentially play a role in such aggregation. 
Aoki et al. (34) showed that a cysteine residue in the hydropho­
bic transmembrane sequence was important for Golgi reten­
tion, and this cysteine is conserved in j34Gal-T2, but not 
/34Gal-T3 or the snail /34-GlcNAc-transferase (Fig. 4). The 
implications of this are not known at present,
The fine specificity of the three j84-Gal-transferases for dif­
ferent types of glycoconjugates and branch points of oligosac­
charide structures needs to be determined in comparative as­
says with recombinant forms of the enzymes. Here, we have 
correlated the activities of recombinant soluble j34Gal-T2 and 
|34Gal-T3 with purified bovine milk enzyme, which potentially 
contains other /3-Gal-transferase activities than j34Gal-Tl. The 
substrate specificities with monosaccharides and simple deriv­
atives were similar (Table I). /34Gal-T2 had a lower Km for 
UDP-Gal than both bovine milk /34-Gal-transferase and /34Gal- 
T3 (Table II) and also a lower Km for the best acceptor sub­
strates (benzyl-/3-GlcNAc and GlcNAc) used in this study. At 
1 ’ ;^h concentrations of acceptor substrates (benzyl-/3-GlcNAc 
and GlcNAc), all three enzymes showed inhibition of activities, 
but j34Gal-T2 was the most sensitive (Fig. 6). Inhibition of 
j34Gal-Tl was previously noted at concentrations in excess of 
20-30 mM (61), but in the present study, this was seen at 
higher concentrations.
The substrate specificity of /34Gal-Tl is modulated by a-lac­
talbumin (72, 73), A similar modulation of the substrate spec* 
ificity was found for ]34Gal-T2, whereas /34Gal-T3 was largely 
insensitive (Fig. 5). Interestingly, mice rendered deficient in 
/34Gal-Tl were shown not to produce lactose (39, 40). This 
suggests that /34Gal-T2 is not expressed in lactating mammary 
glands. Differences in sensitivity to a-lactalbumin modulation 
of putative members of the |34-Gal-transferase family have 
previously been observed. Two distinct porcine trachea /34-Gal- 
transferases have been separated, and one of these was shown 
to be insensitive to a-lactalbumin. similar to /34Gal-T3 (36). 
The homologous /34-GlcNAc-transferase identified in snail is 
apparently not sensitive to a-lactalbumin (74); however, an­
other putative member of this enzyme family, a /34-GalNAc- 
transferase, was found to be modulated by a-lactalbumin (75).
As j34Gal-Tl and /34Gal-T2 were most similar in sequence 
and seemed to have similar properties, the specificity of /34Gal- 
T3 was studied in more detail. Analysis of /34Gal-T3 and bovine 
milk /3-Gal-transferase with gly colipid substrates showed that 
both enzymes utilize Lc3Cer efficiently, and characterization of 
the product formed by /34Gal-T3 using 1H NMR clearly estab­
lished the expected product as being nLc4 with a Gal/31—
% 4
4GlcNAc linkage. Interestingly, marked differences in activi­
ties were found with the extended substrate nLc5Cer (Table 
III). In contrast to the bovine milk enzyme, j34Gal-T3 poorly 
utilized nLcgCer, which may suggest that /34Gal-Tl is involved 
in all steps of the synthesis of poly-N-acetyll act os amine chain 
extension, whereas /34Gal-T3 may be mainly involved in the 
synthesis of the first JV-acetyllactosamine unit. Differential 
expression of /34-Gal-tr ansferases may be part of the regulation 
of poly-2V-acetyllactosamine chain extension, which appears to 
be development ally regulated (76, 77).
The differences found in the kinetic properties of the three
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|3-Gal-transferases may relate to past findings of p-Gal-trans- 
ferase activities in different organs and in B cells of rheumatoid 
arthritis patients. Furukawa et al. (37) showed that liver /34- 
Gal-transferase activity was near 20-fold higher with asialo- 
agalactotransferrin compared with asialo-agalacto-IgG, 
whereas the activity found in T and B cells showed only a
4-5-fold difference with the two substrates. The /34-Gal-trans- 
ferase activity in B cells of rheumatoid arthritis patients ap­
pears to be similar to that in B cells of healthy controls with 
several substrates, including asialo-agalactotransferrin (37) 
and jB-GlcNAc-phenylisothiocyanate-bovine serum albumin 
(78), but different with asialo-agalacto-IgG (37). Furthermore, 
the Km for UDP-Gal of /3 4-Gal-transferase activity in B cells of 
rheumatoid arthritis patients was 2-fold higher (35.6 pM.) than 
that in normal B cells (17.6 pM) (37). Finally, the activity in B 
cells with asialo-agalactotransferrin was more sensitive to 
a-lactalbumin inhibition than the activity with asialo-agalacto- 
IgG. It is intriguing that /34Gal-T2 has a lower Km for UDP-Gal 
than the other two enzymes and that this is close to that found 
in normal B cells (37). In addition, /34Gal-T2 was slightly less 
sensitive to a-lactalbumin inhibition, in agreement with the 
activity with asialo-agalacto-IgG found in normal B cells. A 
number of studies have concluded that there was no change in 
/3-Gal-transferase activity in B cells of rheumatoid arthritis 
patients (79, 80). With the new insight into the /3-Gal-transfer­
ase family, which includes at least two additional genes, it is 
possible that the contradictory findings of Furukawa et al. (37) 
can be explained by a model with two ¡3-Gal-transferases with 
different kinetic parameters expressed in normal B cells and a 
selective down-regulation of one in B cells of rheumatoid ar­
thritis patients. j34Gal-T2 may be a candidate for such a second 
enzyme, and studies are now in progress to determine this.
/34Gal-T2 and j34Gal-T3 were differentially expressed in hu­
man organs (Fig. 6). In contrast, /34-Gal-Tl is considered to be 
more widely expressed, and extensive analysis of the regula­
tory elements indicated that this gene is a ubiquitously ex­
pressed housekeeping gene (81). However, a detailed compar­
ative analysis of the expression patterns of the three enzymes 
at the level of individual cell types is not available at present. 
Two additional members of this gene family have been cloned, 
and expression is ongoing; and it is possible that these may 
represent |34-Gal-transferases with different expression pat­
terns. Analysis of /3 4-Gal-transferase activities in extracts of 
organs from mice deficient in j34 Gal-Tl showed that only 5% 
activity remain in liver and spleen (40); however, 30% activity 
was left in brain, although the total activity in this organ was 
low (39)* Interestingly, expression of |34Gal-T2 and |34Gal-T3 
could not be detected in liver, but /34Gal-T3 was weakly ex­
pressed in spleen and brain. Studies of j34-Gal-transferase ac­
tivities by Shur and co-workers (39) have generally been per­
formed with 20-30 mM iV-acetylglucosamine, based on kinetic 
properties of cell-surface /34-Gal-transferase activity in mouse 
sperm and embryonic carcinoma cell lines (6, 61). In studies of 
sperm ¡34-Gal-transferase activity, the optimal acceptor sub­
strate concentration was determined to be 20 ium GlcNAc, with 
some inhibition at higher concentrations. In this study, we 
show that all three 04-Gal-transferases are inhibited, but that 
/34Gal-T2 is inhibited at lower concentrations than both bovine 
milk j34-Gal-transferase and /34Gal-T3 (Fig. 6). Thus, analysis 
of galactosyltransferase activities at high acceptor substrate
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Fig. 11. Fluorescence in situ hybridization of j34Gal-T2 and 
/34Gal-T3 to metaphase chromosomes. A, the /34Gal-T2 probe (PI 
DNA from clone DPMC-HFF10638:515:G9) labeled band lp32-33. J9, 
the /34Gal-T3 probe (PI DNA from clone DPMC-HFF1-0288-D2) labeled 
lq23.
concentrations may be misleading for the actual activity pres­
ent. Since mice deficient in /34Gal-Tl developed normally be­
fore birth and only exhibited reduced growth and lethality after 
birth, it is likely that other /34-Gal-transferases besides /34Gal- 
T1 are functioning in fetal life. Analysis of serum glycoproteins 
of 10-week-old mice deficient in j34Gal-Tl showed a marked 
decrease in galactosylation (40), suggesting that the major 
)34-Gal-transferase involved in the synthesis of these glycopro­
teins is |34Gal-Tl, In contrast, Lu et a l (39) found that despite 
a lack of detectable /34-Gal-transferase activity in salivary 
glands, a normal level of Gal/31-4GlcNAc terminating chains 
in salivary gland extracts was found by lectin analysis and 
a2,6-sialylation. It is therefore likely that another /34-Gal- 
transferase besides /34Gal-Tl is active in salivary glands.
It is clear that the single step of forming the GaljSl- 
4GlcNAc/3 linkage is performed by a family of /34-Gal-trans­
ferases and that each member of this family may play a distinct 
role in different cells. A similar finding was made for the 
initiation step of GalNAc and Man O-glycosylation in animals 
and yeast. Large families of homologous enzymes with distinct 
but overlapping specificities and different expression patterns 
perform a reaction previously considered to be maintained by a 
single enzyme (23, 54). The a2-fucosyltransferases (82), «3/4- 
fucosyltransferases (83), and some of the sialyltransferases (24) 
are other examples of this phenomenon of partial redundancy. 
The findings that the genes in most glycosyltransferase fami­
lies have diverged considerably and show only 30->50% se­
quence similarities combined with differential expression pat­
terns suggest that each member of these gene families plays a 
distinct role. The seemingly similar enzyme activities deter­
mined in i?i vitro assays may not fully reveal the in vivo func­
tions of these enzymes.
From the present status of cloning of glyco syltr ansfer ases, 
one may predict that there is no requirement for primary 
sequence similarities between gly cosyltr ansfer ases utilizing
the same donor or acceptor substrates per se. Analysis of the 
known glycosyltransferase gene families shows that these have 
common specificities for the nucleotide of the donor substrate 
and the anomeric configuration of the linkage formed, whereas 
the acceptor substrate and the linkage positions formed seem 
to be more variable. The sialyltransferases all utilize CMP- 
NeuAc and form a-anomeric linkages, but they form linkages to 
several different acceptors (Gal, GalNAc, GlcNAc, and NeuAc) 
and at different positions (C-3, C-6, and C-8) (24). Although all 
members of this gene family share some sequence similarity, it 
is apparent that members forming the same linkage type have 
higher sequence similarity. The a 1,3/4-fucosyltr ansfer ase fam­
ily utilizes GDP-Fuc and forms either a 1-3 or a 1-4 linkages to 
GlcNAc (84). The a3-GalNAc-transferase family utilizes UDP- 
Gal or UDP-GalNAc and forms a 1-3 linkages to Gal (27). The 
/36-GlcNAc-transferases use different acceptor substrates (28), 
The polypeptide GalNAc-tr ansfer ase family generally utilizes 
UDP-GalNAc, but one member (GalNAc-T2) was recently 
found also to utilize UDP-Gal (23, 44). Finally, the snail |34~ 
GlcNAc-transferase homologues to the /34-Gal-transferase fam­
ily utilize UDP-GlcNAc, but form the same linkage. Therefore, 
specific functions of a newly identified homologous gene in a 
glycosyltransferase family are not easily predicted even though 
homologous gly cosyltr ansfer ases recognize the same nucleotide 
of the donor substrate and form the same anomeric configura­
tion of linkages.
The existence of multiple /34-Gal-transferases has implica­
tions for interpretation of past studies of the expression pattern 
and biological functions previously assigned to /34Gal-Tl; this 
is what was learned from analysis of mice deficient in /34Gal- 
TL Detection of gene expression of /34Gal-Tl by Northern or in 
situ hybridization is likely to be representative of genuine 
j34Gal-Tl expression, but analysis of enzyme activities in ex­
tracts or body fluids may represent all or any of the /34-Gal- 
transferases, and knowledge of the kinetic parameters of each 
of the enzymes is required to ascertain that all activities are 
measured. Immunodetection with antibodies prepared against 
purified rather than recombinant /34-Gal-transferases may 
likewise be directed toward any or several of the enzymes in the 
family.
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Note Added in Proof—A fourth human /34-galactosyltranaferase was 
recently cloned and expressed. (Sato, T., Furukawa, K., Bakker, H., Van 
den Eijnden, D. H. (1997) Glycoconj. J . 14, (suppl.) 46). This gene 
showed lower sequence similarity to /34 Gal-Tl than the two genes 
reported here, and the expressed enzyme was not alactalbumin-sensitive.
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